Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of lurasidone versus placebo and olanzapine in acutely psychotic patients with schizophrenia
ISRCTN33909010Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jan 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of lurasidone in schizophrenia (4 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Change in total PANSS score from baseline to end of 6-week double-blind treatment. Started Jan 2008; status: completed.
02
Drugs
lurasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ISRCTN33909010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN33909010.